在癌症治疗中准RSK2:对天然产品的审查
Tianhui Wu1,2, Ziming Chen1, Xin Liu1
1School of Chemistry and Life Science, Suzhou University of Science and Technology, Suzhou, China.
Anti-cancer agents in medicinal chemistry
|September 9, 2024
概括
P90核糖体S6激酶2 (RSK2) 是细胞生长和癌症进展的关键调节剂. 这篇评论强调了RSK2的重点.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 药理学 药理学是指药理学的学科.
背景情况:
- P90核糖体S6激酶2 (RSK2) 是一种涉及细胞生长调节的氨酸/氨酸激酶.
- RSK2位于MAPK/ERK通路的下游,影响癌细胞的增殖,亡和转移.
- RSK2是各种癌症的有效治疗标,包括乳腺癌和黑色素瘤.
研究的目的:
- 审查RSK2在癌症发展和进展中的作用.
- 讨论当前的RSK2抑制剂及其作用机制.
- 探索天然产品作为RSK2抑制剂在癌症治疗中的潜力.
主要方法:
- 关于RSK2在癌症中的功能研究的文献综述.
- 对RSK2抑制剂当前临床试验的分析.
- 对针对RSK2.2的天然产品化合物的检查.
主要成果:
- RSK2失调促进了瘤细胞的增殖,抑制了细胞亡,停止了细胞循环,并增强了转移.
- 现有的RSK2抑制剂向N端激酶域 (NTKD) 或C端激酶域 (CTKD).
- 天然产品作为新型RSK2抑制剂具有潜在的抗癌活性.
结论:
- RSK2是癌症治疗的重要治疗标.
- 对RSK2抑制剂,特别是天然产品的进一步研究是有必要的.
- 这一综述为RSK2向疗法的临床应用提供了基础.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Electron Transport Chain: Complex I and II
12.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.2K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K


